In adults with seasonal influenza A virus infection, the combination of the drugs oseltamivir (tamiflu) and zanamivir (relenza) is less effective than oseltamivir monotherapy and not significantly more effective than zanamivir monotherapy. This key finding comes from a randomized, placebo-controlled trial— in adults presenting with influenza symptoms at general practices throughout France during the seasonal influenza epidemic in 2008-2009— carried out by Catherine Leport from the University of Paris, France, and colleagues, and reported in this week’s PLoS Medicine.
